MBRX Moleculin Biotech Inc
Company Analysis
Latest News
🔴 Moleculin Biotech is trading 5.65% down today — with no clear explanation
Moleculin Biotech is trading 5.65% lower at $0.53 after opening-day weakness on September 23, 2026, with no clear explanation for the decline. - The company...
🟢 Moleculin Biotech is trading 6.2% up today after Mexico grants patent for lung-targeted Annamycin technology
Moleculin Biotech is trading up 6.2% now at $0.60 after Mexico granted a patent protecting its lung-targeted liposomal Annamycin technology. - Announced...
🔴 Moleculin Biotech is trading 6.18% down in pre-market with catalyst unclear
Moleculin Biotech is trading 6.18% down at $0.53 in pre-market, with no company-specific announcement identified for September 23, 2026. - Recent coverage...
🟢 Moleculin Biotech is trading 11.57% up today amid biotech sector gains
Moleculin Biotech is trading 11.57% higher at $0.58, mainly as biotech gains and recovery buying follow the prior selloff. - Shares fell 32.71% to $0.52 on...
🟢 Moleculin Biotech is trading 8.59% up today — following sharp 32.71% decline
Moleculin Biotech is trading 8.59% up at $0.56 following a sharp 32.71% decline, with no confirmed company-specific catalyst identified. - It closed at $0.52...
🟢 Moleculin Biotech is trading 5.56% up in pre-market with no company-specific explanation for the rise identified
Moleculin Biotech is trading 5.56% up now at $0.55 after falling sharply to $0.52 on September 21, 2026; no new company-specific announcement explaining the...
Moleculin Faces Nasdaq Exile — Can a Hearing Save a Stock That Already Lost Its Safety Net?
Shares of Moleculin Biotech cratered 29.9% to $0.54 on September 21, 2026, after the clinical-stage drugmaker disclosed that Nasdaq has moved to kick it off...
🔴 Moleculin Biotech is trading 29.94% down today after Nasdaq’s delisting determination
Moleculin Biotech is trading 29.94% down now at $0.54 after investors reacted to Nasdaq’s September 15, 2026 staff determination, disclosed September 18,...
🔴 Moleculin Biotech is trading 5.57% down in pre-market after a Nasdaq delisting determination
Moleculin Biotech is trading 5.57% down in pre-market at $0.73 after investors reacted to a Nasdaq delisting determination disclosed on September 18, 2026. -...
🔴 Moleculin Biotech is trading 5.57% down in after-hours trading after receiving a Nasdaq delisting notice
Moleculin Biotech is trading 5.57% down now at $0.73 after investors reacted to a Nasdaq delisting determination disclosed on September 18, 2026. - The...
Moleculin Biotech Receives Nasdaq Delisting Notice for Minimum Bid Price Requirement
Moleculin Biotech, Inc. (MBRX) received a delisting determination letter from Nasdaq on September 15, 2026, for failing to meet the $1.00 minimum bid price...
🟢 Moleculin Biotech is trading 5% up today as broader risk appetite returned across growth stocks
Moleculin Biotech is trading 5.41% up now at $0.77 as broader risk appetite returned across growth stocks on September 17, 2026. - No new company-specific...
🟢 Moleculin Biotech is trading 2.6% up in pre-market after announcing new September Annamycin data presentations
Moleculin Biotech is trading at $0.80, up 2.6% in pre-market after announcing new Annamycin data presentations. - On September 14, Moleculin Biotech announced...
🟢 Moleculin Biotech is trading 5.78% up today in pre-market after new Annamycin data presentations for September meetings
Moleculin Biotech is trading 5.78% up in pre-market at $0.82 after announcing new Annamycin presentations for three September scientific meetings. - The...
Moleculin to Present New Annamycin Data at AACR Pancreatic Cancer Conference
Moleculin Biotech, Inc. (MBRX) announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific conferences...
🟢 Moleculin Biotech is trading 11.87% up today after encouraging interim MIRACLE trial data for Annamycin
Moleculin Biotech is trading 11.87% up now at $0.80 after investors responded to encouraging interim MIRACLE trial data for Annamycin. - Complete remission...
Moleculin's Leukemia Drug Shows Promise Without Heart Damage — But Can a $14 Million Company Afford to Cross the Finish Line?
Shares of Moleculin Biotech jumped 7.7% to $0.77 on September 14, bucking a broader market selloff, after investors digested encouraging interim data from the...
🟢 Moleculin Biotech is trading 8% up today on higher remission rates without cardiotoxicity
Moleculin Biotech is trading at $0.77, up +7.97%, after encouraging interim Phase 3 Annamycin data highlighted higher remission rates in relapsed or refractory...
🟢 Moleculin Biotech is trading 6% up in pre-market after encouraging interim Phase 3 Annamycin data
Moleculin Biotech is trading 6% up at $0.76 after investors reacted to encouraging interim Phase 3 Annamycin data presented through the H.C. Wainwright...
Moleculin Biotech Reports Higher Phase 3 AML Remissions With No Cardiotoxicity
Moleculin Biotech released its H.C. Wainwright 28th Annual Global Investment Conference presentation on September 11, 2026. The update features interim Phase 3...